Infliximab is a monoclonal anti–tumor necrosis factor (TNF)-α antibody indicated in steroid-resistant and/or fistulizing Crohn disease (CD). Reactivation of chronic viral hepatitis as well as opportunistic infections have been reported as adverse effects,1,2 but the impact of such drugs on patients' virological and immunological status remains unknown.3
Filippi J, Roger P, Schneider SM, et al. Infliximab and Human Immunodeficiency Virus Infection: Viral Load Reduction and CD4+ T-Cell Loss Related to Apoptosis. Arch Intern Med. 2006;166(16):1783–1784. doi:10.1001/archinte.166.16.1783
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: